These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6111081)

  • 1. A chronically hypoprolactinemic rat model: administration of lergotrile mesylate by osmotic minipump.
    Mills DE; Buckman MT; Peake GT
    Proc Soc Exp Biol Med; 1981 Mar; 166(3):438-41. PubMed ID: 6111081
    [No Abstract]   [Full Text] [Related]  

  • 2. Avoidance behavior and plasma prolactin levels in lergotrile mesylate treated rats.
    Yelvington DB; Weiss GK; Ratner A
    Pharmacol Biochem Behav; 1986 Jan; 24(1):67-70. PubMed ID: 2868466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action.
    Clemens JA; Smalstig EB; Shaar CJ
    Acta Endocrinol (Copenh); 1975 Jun; 79(2):230-7. PubMed ID: 166535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of the dopamine agonist, lergotrile mesylate, on prolactin secretion in women.
    Leebaw W; Lee L; Woolf P
    Acta Endocrinol (Copenh); 1978 Jan; 87(1):12-8. PubMed ID: 579527
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of lergotrile mesylate and methysergide on morphine induced increase in prolactin release.
    Ratner A; Woo W; Yelvington D; Torres K
    Proc West Pharmacol Soc; 1981; 24():335-9. PubMed ID: 6114495
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of the effects of CB-154 and lergotrile mesylate on prolactin and growth hormone secretion in mice.
    Sinha YN; Salocks CB; VanderLaan WP
    Horm Metab Res; 1976 Sep; 8(5):332-6. PubMed ID: 989755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin binding to R3230AC mammary carcinoma and liver in hormone-treated and diabetic rats.
    Smith RD; Hilf R; Senior AE
    Cancer Res; 1977 Feb; 37(2):595-8. PubMed ID: 188551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the antiparkinsonism efficacy of lergotrile.
    Lieberman A; Miyamoto T; Battista AF; Goldstein M
    Neurology; 1975 May; 25(5):459-62. PubMed ID: 166332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in blood pressure in normal and spontaneously hypertensive rats by lergotrile mesylate.
    Sved AF; Fernstrom JD
    J Pharm Pharmacol; 1979 Dec; 31(12):814-7. PubMed ID: 43364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the response pattern of aged female rats to treatment with lergotrile mesylate.
    Wiggins C; Wise PM; Ratner A
    Proc Soc Exp Biol Med; 1985 Jun; 179(2):173-9. PubMed ID: 2859599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of 2-bromo-alpha-ergocryptine and 2-chloro-alpha-methylergoline-8beta-acetonitrile (lergotrile mesylate) on the prolactin secretion of the ewe.
    Hooley RD; Fell LR; Findlay JK
    Acta Endocrinol (Copenh); 1977 Dec; 86(4):722-7. PubMed ID: 411304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibitory effect of an ergoline derivative (lergotrile, compound 83636) on prolactin secretion in man.
    Lemberger L; Crabtree R; Clemens J; Dyke RW; Woodburn RT
    J Clin Endocrinol Metab; 1974 Sep; 39(3):579-84. PubMed ID: 4416328
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolism of lergotrile to 13-hydroxy lergotrile, a potent inhibitor of prolactin release in vitro.
    Parli CJ; Schmidt B; Shaar CJ
    Biochem Pharmacol; 1978 May; 27(9):1405-8. PubMed ID: 29651
    [No Abstract]   [Full Text] [Related]  

  • 14. The effects of dopamine, bromocriptine, lergotrile and metoclopramide on prolactin release from continuously perfused columns of isolated rat pituitary cells.
    Yeo T; Thorner MO; Jones A; Lowry PJ; Besser GM
    Clin Endocrinol (Oxf); 1979 Feb; 10(2):123-30. PubMed ID: 34491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of hyperprolactinemia with a new ergot derivative, lergotrile mesylate.
    Sherman BM; Swanson JA; Chapler FK
    Fertil Steril; 1978 Mar; 29(3):291-5. PubMed ID: 565303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin binding to mammary gland, 7,12-dimethylbenz(a)-anthracene-induced mammary tumors, and liver in rats.
    Smith RD; Hilf R; Senior AE
    Cancer Res; 1976 Oct; 36(10):3726-31. PubMed ID: 821605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of lergotrile on 3,4-dihydroxyphenylacetic acid (DOPAC) concentration and dopamine turnover in rat brain.
    Fuller RW; Perry KW
    J Neural Transm; 1978; 42(1):23-35. PubMed ID: 641542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lergotrile mesylate: an in vivo dopamine agonist which blocks dopamine receptors in vitro.
    Kebabian JW; Calne DB; Kebabian PR
    Commun Psychopharmacol; 1977; 1(4):311-8. PubMed ID: 615694
    [No Abstract]   [Full Text] [Related]  

  • 19. Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin.
    Rose DP; Gottardis M; Noonan JJ
    Anticancer Res; 1983; 3(5):323-5. PubMed ID: 6139974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonist-induced hyperglycemia in rats: effects of lergotrile mesylate.
    Schmidt MJ
    Eur J Pharmacol; 1979 Oct; 59(1-2):95-101. PubMed ID: 41730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.